Ventus Therapeutics
Waltham
About Ventus Therapeutics
Ventus Therapeutics is a biopharmaceutical company discovering and developing novel small molecule medicines that target the innate immune system to treat autoimmune diseases, inflammatory diseases, and cancer. Ventus' structural immunology platform offers unprecedented insight into mechanisms and molecular structures, combining core capabilities for precisely targeting the innate immune system: proprietary protein engineering capabilities that elucidate innate immune mechanisms, and leading-edge rational and structure-based drug design tools. Ventus has built an emerging pipeline of multiple drug programs addressing key targets in the innate immune system.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $370.1M
- Last round: Grant (Apr 2023)
- Website: ventustx.com
- Phone: 514-397-9517
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/ventus-therapeutics-88545 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.